ProstACT Global: A Phase 3 study of 177Lu rosopatamab tetraxetan (TLX591) plus standard of care (SoC) versus SoC alone in patients with metastatic castration-resistant prostate cancer (mCRPC) Patient Summary What is TLX591? TLX591 comprises a radioactive isotope,...